CONTACT: Jeff Smith, Sunridge International T: +1-480-837-6165 e-mail: [email protected] website: www.sunridgeint.com MEDIA: Victor Webb, Marston Webb ...
FREISING-WEIHENSTEPHAN, Germany , September 28, 2010 /PRNewswire/ -- Pieris AG ( http:www.pieris-ag.com/ ) announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines ...
NEW BRUNSWICK, N.J., Sept. 27 Johnson & Johnson (NYSE: JNJ) today announced that it has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic ...
MANHASSET, N.Y., Sept. 27 Sixty percent of U.S. adults are not familiar with sepsis, despite the fact that more than 200,000 Americans die from it every year, making sepsis one of the leading causes of death in the nation. Lack of awareness is ...
SINGAPORE, Sept. 27 S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC). The trial is sponsored by ...
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626 ...
BEIJING , Sept. 21 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China -based advanced in-vitro diagnostic ("IVD") company, today announced that it plans to offer, subject to ...
Results Announced at the 2010 International Urogynecological Association (IUGA) and International Continence Society (ICS) Annual Meeting MINNEAPOLIS , Sept. 21 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading ...
CHENGDU, China , Sept. 21 /PRNewswire-Asia-FirstCall/ -- China SHESAYS Medical Cosmetology Inc. (OTC Bulletin Board: CSAY) ("China SHESAYS" or the "Company"), which operates a chain of specialized medical cosmetology hospitals, clinics ...
HOUSTON , Sept. 21 /PRNewswire/ -- The popular nutraceutical health supplement, Oxy-Powder® has passed clinical trials for Irritable Bowel Syndrome (IBS) with a 99.9 percent success rate. According to the NIH, approximately 20% of Americans ...
Vanderbilt’s Phase I trial of VU319 demonstrates promising results for Alzheimer’s and schizophrenia
Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with undetectable MRD.
Hypovolemic phlebotomy, removing 10% of blood before liver surgery, can cut transfusion needs by 50%, offering a safe, cost-effective way to reduce surgery risks.
Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, suggesting lasting clinical benefits.
Discover how FarrSight ®-Twin technology utilizes digital twins to revolutionize cancer clinical trials by simulating patient responses.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers